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Coronary artery bypass grafting is pivotal in the contemporary management of complexDepartment of
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http://dx.doi.org/1coronary artery disease. Interpatient variability to antiplatelet agents, however, harbors the
potential to compromise the revascularization beneﬁt by increasing the incidence of adverse
events. This study was designed to deﬁne the impact of dual antiplatelet therapy (dAPT) on
clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery.
We randomly assigned 219 aspirin-resistant patients according to multiple electrode
aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy
(300 mg). The primary end point was a composite outcome of all-cause death, nonfatal
myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months post-
operatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of
patients randomized to aspirin-monotherapy (relative risk 0.61, 95% conﬁdence interval 0.25
to 1.51, p[ 0.33). No signiﬁcant treatment effect was noted in the occurrence of the safety end
point. The total incidence of bleeding events was 25% and 19% in the dAPT and aspirin-
monotherapy groups, respectively (relative risk 1.34, 95%conﬁdence interval 0.80 to 2.23, p[
0.33). In the subgroup analysis, dAPT led to lower rates of adverse events in patients with a
body mass index >30 kg/m2 (0% vs 18%, p <0.01) and those <65 years (0% vs 10%, p[ 0.02).
In conclusion, the addition of clopidogrel in patients found to be aspirin resistant after cor-
onary artery bypass grafting did not reduce the incidence of adverse events, nor did it increase
the number of recorded bleeding events. dAPT did, however, lower the incidence of the pri-
mary end point in obese patients and those <65 years.  2014 The Authors. Published by
Elsevier Inc. All rights reserved. (Am J Cardiol 2014;113:1660e1667)Coronary artery bypass grafting (CABG) remains the
standard of care in the management of complex coronary
artery disease.1 Improvements in postoperative outcomes
rely both on technical reﬁnements of the procedure and
optimization of medical management. The long-term bene-
ﬁts of CABG depend upon the durability of nonobstructed
ﬂow through bypass grafts. Inhibition of platelet aggreg-
ability plays a crucial role in improving graft patency.
Aspirin is currently the most commonly employed anti-
platelet agent after CABG.2 Dual antiplatelet therapy
(dAPT) may improve the venous graft patency,3 but this
beneﬁt has not been reliably reproduced in a wider clinical
arena.4 The combination of clopidogrel and aspirin results in
the cumulation of their individual antiaggregatory effects,
because their individual mechanisms of antiplatelet activity
differ.5 Dual platelet inhibition may be of particularCardiac Surgery, University Hospital Center Zagreb,
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0.1016/j.amjcard.2014.02.024importance in patients exhibiting single antiplatelet drug
resistance.6 Deﬁning the role of dAPT in the contemporary
surgical practice is paramount before recommending it
without reservations, however, as it may increase the inci-
dence of bleeding.7 The incidence of low response to aspirin
is not uniform across the available spectrum of platelet
function tests. It has been reported to range from 1% to 45%.8
Although clear outlines of this phenomenon remain to be
deﬁned, its adverse clinical impact has been validated.9 We
hypothesized that augmentation of platelet inhibition with
clopidogrel in patients with high postoperative on-aspirin
platelet reactivity would lead to improvement in clinical
outcomes. The convergence of the clinical impact of aspirin
resistance with the beneﬁcial effects of dAPT in other clinical
scenarios was the foundation of this trial’s design. This is, to
the best of our knowledge, the ﬁrst prospective randomized
study that selectively implemented dAPT after CABG in
patients with aggregometry-documented aspirin resistance.
Methods
The study was conducted at the University Hospital
Center Zagreb in Zagreb, Croatia. Patient enrollment started
in June 2010 and was completed in February 2013. Details of
the study design, eligibility, and exclusion criteria have been
published previously.10 Brieﬂy, adult patients scheduled to
undergo elective primary CABG were eligible for enrollment.
Exclusion criteria included valvular pathology warrantingwww.ajconline.org
Figure 1. Patient eligibility, randomization, and follow-up. BARC ¼ Bleeding Academic Research Consortium; PCI ¼ percutaneous coronary intervention;
PFT ¼ platelet function testing.
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antiplatelet management, anticoagulation, and critical condi-
tion before randomization. Patients who underwent CABG
following a recent acute coronary syndrome were excluded,
as there are data to suggest that they might beneﬁt from
dAPT.11 On postoperative day (POD) 4, patients underwent
an aggregometry-based assessment of their on-aspirin platelet
reactivity. Patients found to be aspirin responders were
excluded from further analysis, whereas aspirin-resistant pa-
tients were randomized into either the control or intervention
groups.
The trial was approved by the Ethics committee of the
University Hospital Center Zagreb. Ethical standards in line
with the Declaration of Helsinki were adhered to. Written
informed consent was obtained from all patients before
enrollment.
Multiple electrode aggregometry was used for quanti-
fying platelet reactivity in the study cohort (Multiplate,
Dynabyte, Munich, Germany). Platelet aggregation, as
evaluated by multiple electrode aggregometry, is respon-
sible for the variability in sensor wire impedances. The
numerical multiple electrode aggregometry output describes
the electrical resistance between sensor wires, which is
proportional to platelet adherence.12 Arachidonic acid(0.5 mM) and adenosine diphosphate (ADP, 6.4 mM) were
utilized as platelet agonists for conducting the ASPI and
ADP tests, respectively.
The ASPI test evaluates cyclooxygenase-1-dependent
platelet aggregation and is therefore a surrogate for aspirin
responsiveness. Although aspirin response is better described
as a continuous variable, dichotomizing patients into
“responders” and “nonresponders” is commonly utilized for
research purposes.8 Aspirin resistance in the present study
was deﬁned in linewith previous reports stratifying individual
patient responsiveness into quartiles.13 Patients were classi-
ﬁed as aspirin resistant if their ASPI test values exceeded the
population’s 75th percentile cut-off point (area under the
curve [AUC] 30).13 This deﬁnition was substantiated by
data from multiple other sources.14,15
Having met the inclusion criteria for aspirin resistance on
POD 4, patients scheduled for isolated CABG were
randomly allocated into either continuation on 300 mg of
aspirin (control group) or enhancement of platelet inhibition
with 75 mg of clopidogrel plus 300 mg of aspirin (dAPT
group). Randomization software was used for patient allo-
cation into the control or intervention arms.10
Preoperative platelet inhibition with aspirin was main-
tained up to the day of surgery. Conversely, patients
Table 1
Baseline demographic and clinical proﬁles (n ¼ 219)
Variable Aspirin
Monotherapy
(n ¼ 107)
Aspirin Plus
Clopidogrel
(n ¼ 112)
p*
Age (yrs) 65  9 65  8 0.69
Male gender 82 (77) 83 (74) 0.75
BMI (kg/m2) 30  4 29  4 0.21
EuroSCORE 3.6  3.7 3.5  3.0 0.44
LVEF (%) 55  10 53  10 0.16
Hyperlipidemia† 103 (96) 108 (96) 1.00
Diabetes mellitus 41 (38) 43 (38) 1.00
Smoker 41 (38) 38 (34) 0.57
Hypertensionz 103 (96) 108 (96) 1.00
Left main narrowing 57 (53) 48 (43) 0.14
Three-vessel coronary disease 80 (75) 88 (79) 0.53
Preoperative platelet reactivity
ASPI test values, AUC 38  28 35  30 0.27
ADP test values, AUC 80  25 77  26 0.47
Preoperative medications
Clopidogrel 27 (25) 37 (33) 0.24
Aspirin 94 (88) 100 (89) 0.83
b blocker 83 (78) 101 (90) 0.02
Angiotensin converting
enzyme inhibitor
67 (63) 61 (54) 0.27
Statin 104 (97) 108 (96) 1.00
Data are presented as n (%) and mean  SD.
ASPI ¼ cyclooxygenase dependent platelet aggregation; BMI ¼ body
mass index; BP ¼ blood pressure; EuroSCORE ¼ European System for
Cardiac Operative Risk Evaluation; LVEF ¼ left ventricular ejection
fraction.
* Two-tailed p value.
† Hyperlipidemia was deﬁned as any of the following: history of
hypercholesterolemia (low-density lipoprotein cholesterol >3.4 mmol/L or
total cholesterol >5.2 mmol/L), hypertriglyceridemia (>1.7 mmol/L), hyper-
chylomicronemia or use of lipid-lowering medications to achieve target lipid/
lipoprotein values.
z Hypertension was deﬁned as 2 or more systolic BP measurements
140 mm Hg or diastolic BP readings 90 mm Hg, or use of antihyper-
tensive medications to achieve the desired BP values in patients with a
history of high BP.
Table 2
Perioperative details and postoperative medication use
Aspirin
Monotherapy
(n ¼ 107)
Aspirin Plus
Clopidogrel
(n ¼ 112)
p*
Perioperative data
Left internal mammary use 101 (94) 104 (93) 0.78
Cross-clamp time (minutes) 57  22 59  22 0.45
CPB time (minutes) 86  25 87  28 0.62
Postoperative AF 27 (25) 36 (32) 0.30
Postoperative inotrope use 31 (29) 36 (32) 0.66
Postoperative platelet reactivity
ASPI test values, AUC 53  22 60  29 0.19
ADP test values, AUC 97  31 95  34 0.89
Postoperative medications
Clopidogrel 0 112 (100) <0.01
Aspirin 107 (100) 112 (100) 1.00
b blocker 101 (94) 101 (90) 0.31
Angiotensin-converting
enzyme inhibitor
12 (11) 17 (15) 0.43
Statin 100 (93) 104 (93) 1.00
Data are presented as n (%) and mean  SD.
AF ¼ atrial ﬁbrillation; ASPI ¼ cyclooxygenase dependent platelet
aggregation; CPB ¼ cardiopulmonary bypass.
* Two-tailed p value.
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continued approximately 5 days before the surgical proce-
dure. Tepid cardiopulmonary bypass and cardioplegic arrest
were used in all study patients. Myocardial preservation was
based on a combination of anterograde and retrograde car-
dioplegia. Postoperatively, patients typically received a b
blocker, hydroxy-methyl-glutaryl-CoA reductase inhibitor,
peptic ulcer prophylaxis, and a diuretic. Angiotensin-con-
verting enzyme inhibitors were administered selectively and
titrated to effect. Aspirin was typically administered within
the ﬁrst 6 hours of surgery. In aspirin nonresponders, the
postoperative antiplatelet regime was then re-evaluated on
POD 4 in line with the study protocol.
The primary efﬁcacy end point was the incidence of
major adverse cardiac and cerebrovascular events (MAC-
CEs) at 6 months. MACCE was a composite outcome
including all-cause mortality, nonfatal myocardial infarction
(MI), cerebrovascular accident, and cardiovascular reho-
spitalization. The secondary outcomes were bleeding events
and individual MACCE components. We adhered to theBleeding Academic Research Consortium deﬁnitions in
presenting the safety end point data.16 The Joint European
Society of Cardiology/American College of Cardiology
Foundation/American Heart Association/World Heart
Federation Task Force for the redeﬁnition of MI was
implemented in patients suspected to have ischemic
myocardial injury.16 Patients with new focal neurologic
deﬁcits lasting >24 hours or those having an acute cerebral
lesion on an imaging study were considered to have had a
stroke.17
The study was designed to analyze the incidence of
MACCE at 6 months, on an intention-to-treat basis, in
aspirin-resistant patients randomized to either continue on
aspirin monotherapy or receive dual inhibition of platelet
aggregation. The sample size required to test the null hy-
pothesis was determined by an exact binomial test power
analysis.18 The minimum effect size was 10%. Accounting
for an estimated 10% loss to follow-up, 219 patients were
required to test the null hypothesis with an a value of 0.05
and a power of 0.8. An additional per-protocol analysis of
the safety end point was performed in patients adhering to
the study protocol. The continuous data are presented as
mean values with their standard deviation. Categorical
variables are presented as absolute numbers with percent-
ages. The Mann-Whitney U test was used to analyze
continuous data between the control and intervention
groups. Comparisons among categorical variables were
performed with Fisher’s exact test. Changes in the platelet
reactivity in response to surgery were evaluated with the
Wilcoxon matched-pairs test. Relative risks (RRs) were
used as a measure of the association between the interven-
tion and clinical outcomes. The respective 95% conﬁdence
intervals (CIs) were provided. A two-tailed p value <0.05
was considered to be statistically signiﬁcant for all deployed
Figure 2. Increases in ASPI test values in the aspirin-monotherapy (A) and dual APT groups (B) in response to surgery. Changes in ADP test values in the
aspirin-monotherapy (C) and dual APT groups (D) in response to surgery. *Wilcoxon matched-pairs test. ASPI ¼ cyclooxygenase-dependent platelet
aggregation; Preop ¼ preoperative.
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tained and provided for comparisons likely to result in one-
directional relationships. The data were processed using the
IBM SPSS Statistics software package (version 20.0;
Somers, New York) and Statpages.org.
Results
During the recruitment period, 2,034 patients were
screened for eligibility. A total of 224 aspirin-resistant pa-
tients with CABG were randomly assigned to receive aspirin
only (n ¼ 110) or aspirin plus clopidogrel (n ¼ 114). An
overview of the patient enrollment and randomization is
shown in Figure 1. The baseline patient demographic and
clinical proﬁles were well balanced between the 2 groups(Table 1). Approximately, 3/4 of the patients were men, and
the majority of them had three-vessel disease, which is
representative of the contemporary cardiac surgical practice.
Beta blockers were utilized more commonly in the dAPT
group before surgery. The use of other preoperative medi-
cations, including antiplatelet agents, did not differ signiﬁ-
cantly between the groups (Table 1). Perioperative data are
listed in Table 2. Postoperative medication regimes did not
differ between the groups with the notable exception of
clopidogrel utilization, which was subject to the randomi-
zation protocol (Table 2).
There were no differences in preoperative platelet
aggregability between the groups (Table 1). The ASPI test
values evaluated on POD4were also comparable between the
control and intervention groups (Table 2). Postoperative
Table 3
Primary and secondary study outcomes (intention-to-treat analysis)
Aspirin Monotherapy (n ¼ 107) Aspirin Plus Clopidogrel (n ¼ 112) RR (95% CI) p*
Efﬁcacy end points
MACCE 11 (10) 7 (6) 0.61 (0.25e1.51) 0.33
All-cause death 4 (4) 2 (2) 0.48 (0.09e2.55) 0.44
Cardiovascular death 1 (1) 1 (1) 0.96 (0.06e15.08) 1.00
Stroke 4 (4) 1 (1) 0.24 (0.03e2.10) 0.20
Nonfatal MI 1 (1) 1 (1) 0.96 (0.06e15.08) 1.00
Composite MI or stroke or cardiovascular death 5 (5) 3 (3) 0.57 (0.14e2.34) 0.49
Cardiovascular hospitalization 3 (3) 3 (3) 0.96 (0.20e4.63) 1.00
Safety end points
Total bleeding events 20 (19) 28 (25) 1.34 (0.80e2.23) 0.33
BARC 1 19 (18) 23 (21) 1.16 (0.67e2.00) 0.61
BARC 2 0 1 (1) N/A 1.00
BARC 3 1 (1) 4 (4) 3.82 (0.43e33.65) 0.37
BARC 4 0 0 N/A 1.00
BARC 5 0 0 N/A 1.00
Data are presented as n (%).
BARC ¼ Bleeding Academic Research Consortium; N/A ¼ not applicable.
* Two-tailed p value.
Table 4
Subgroup analyses of the primary end point
Aspirin
Monotherapy
Aspirin Plus
Clopidogrel
RR (95% CI) p*
Age (yrs)
65 6/58 (10%) 7/58 (12%) 1.17 (0.42e3.26) 1.00
<65 5/49 (10%) 0/54 N/A 0.02
Sex
Men 7/82 (9%) 6/83 (7%) 0.85 (0.30e2.41) 0.78
Women 4/25 (16%) 1/29 (3%) 0.22 (0.03e1.81) 0.17
BMI, kg/m2
>30 8/45 (18%) 0/41 N/A <0.01
30 3/62 (5%) 7/71 (10%) 2.04 (0.55e7.54) 0.34
EuroSCORE
3 6/48 (13%) 5/48 (10%) 0.83 (0.27e2.55) 1.0
<3 5/59 (8%) 2/64 (3%) 0.37 (0.07e1.83) 0.26
LVEF
>50% 5/66 (8%) 4/63 (6%) 0.84 (0.24e2.98) 1.0
50% 6/41 (15%) 3/49 (6%) 0.42 (0.11e1.57) 0.29
Diabetes mellitus
Yes 7/41 (17%) 3/43 (7%) 0.41 (0.11e1.47) 0.19
No 4/66 (6%) 4/69 (6%) 0.96 (0.25e3.67) 1.0
Three-vessel disease
Yes 8/80 (10%) 6/88 (7%) 0.68 (0.25e1.88) 0.58
No 3/27 (11%) 1/24 (4%) 0.38 (0.04e3.37) 0.61
Left main disease
Yes 8/57 (14%) 2/48 (4%) 0.30 (0.07e1.33) 0.11
No 3/50 (6%) 5/64 (8%) 1.30 (0.33e5.19) 1.0
BMI ¼ body mass index; EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation; LVEF ¼ left ventricular ejection fraction;
N/A ¼ not applicable.
* Two-tailed p value.
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the predeﬁned 30 AUC cut-off points discriminating between
aspirin response and resistance. Analogously, the post-
operative ADP test values did not differ between the groups
(Table 2). We have, however, documented a signiﬁcant
postprocedural rise in platelet reactivity in comparison withthe respective preoperative values. The ASPI test values
across the entire cohort increased from 36  29 to 57  26
AUC (p<0.001). This accelerated platelet aggregability was
corroborated by an increase in the ADP values (preopera-
tively: 78  26; postoperatively: 96  33 AUC, p <0.001).
Additional evidence for a hypercoagulable state in the early
postoperative period was found in the dynamics of ﬁbrinogen
levels. We documented a consistent and statistically signiﬁ-
cant increase in ﬁbrinogen concentrations in response to the
surgical procedure (4.1 1.3 vs 6.8 1.4 g/L, p<0.001). The
observed increase in platelet aggregability was seen in both
groups, irrespective of the antiplatelet management strategy
(Figure 2).
Six-month follow-upwas completed in 107 (97%) and 112
(98%) patients in the aspirin monotherapy and dAPT groups,
respectively. The study outcomes are listed in Table 3.
Freedom from MACCE at the completion of the follow-up
period was 90% in the control group and 94% in the dAPT
group. The overall incidence of the primary end point was not
affected by the different antiplatelet management protocols
(6% vs 10%; RR 0.61, 95% CI 0.25 to 1.51, two-tailed p ¼
0.33, one-tailed p ¼ 0.20). A nonsigniﬁcant 43% RR reduc-
tion in the composite end point of MI/stroke/cardiovascular
death was observed with enhancement of platelet inhibition
(two-tailed p ¼ 0.49, one-tailed p ¼ 0.34). The frequency of
individual MACCE components was not affected by the an-
tiplatelet management strategy (Table 3). The causes of death
in the 4 control group patients were stroke, sepsis, necrotizing
tracheitis, and trauma. Two patients in the dAPT group died
during follow-up. One suffered a stroke that eventually led to
his death, whereas the other died of intractable respiratory
failure induced by pneumonia.
An intention-to-treat analysis revealed no statistically sig-
niﬁcant differences in the incidence of bleeding events between
the groups within any of the Bleeding Academic Research
Consortium strata (Table 3). A nonsigniﬁcant increase in the
frequency of total bleeding events was noted with the post-
procedural addition of clopidogrel to aspirin-resistant patients
Coronary Artery Disease/Clopidogrel in Aspirin-Resistant Patients 1665(25% vs 19%; RR 1.34, 95% CI 0.80 to 2.23, two-tailed p ¼
0.33, one-tailed p ¼ 0.17). A post hoc analysis excluding pa-
tients requiring anticoagulation during the follow-up period
was also performed. The incidence of bleeding events in the
per-protocol analysis did not differ signiﬁcantly from the
intention-to-treat analysis (24% in the dAPT group vs 19% in
the aspirin monotherapy group; RR 1.28, 95% CI 0.75 to 2.20,
two-tailed p ¼ 0.39, one-tailed p ¼ 0.23).
The incidence of the primary end point was analyzed
in patient subgroups, stratiﬁed according to the presence
or absence of individual co-morbidities or clinical charac-
teristics. We found a statistically signiﬁcant reduction in the
frequency of MACCE in patients aged <65 years (0% vs
10%, p ¼ 0.02). Analogously, patients with a body mass
index >30 kg/m2 were more likely to beneﬁt from platelet
inhibition with clopidogrel on the background of aspirin
therapy in the prevention of the composite adverse outcome.
The incidences of MACCE among obese patients were 0%
with the dAPT strategy versus 18% in the aspirin-only arm
(p <0.01). The subgroup analyses are listed in Table 4.
dAPT did not increase the incidence of bleeding events in
patients <65 years (22% vs 22%; RR 0.99, 95% CI 0.48 to
2.04, two-tailed p ¼ 1.0, one-tailed p ¼ 0.61). Similarly,
dAPT did not signiﬁcantly increase bleeding among patients
with a body mass index >30 kg/m2 (29% vs 20%; RR 1.46,
95% CI 0.69 to 3.11, two-tailed p ¼ 0.45, one-tailed p ¼
0.23). Similar bleeding rates were noted in all other studied
subgroups (all one- and two-tailed p >0.05).
Discussion
The principal goal of this trial was to measure the impact
of enhanced platelet inhibition with clopidogrel in the
background of standard therapy in aspirin-resistant patients
with CABG on the incidence of adverse events. This is the
ﬁrst prospective randomized study to address the clinical
impact of augmented antiplatelet therapy after CABG in
patients with aggregometry-documented aspirin resistance.
Platelets are anuclear cell fragments harboring unique
adhesion mechanisms that are as critical to arresting
bleeding as they are to atherothrombosis.19 They are at a
junction between inﬂammatory and thrombotic cascades,
playing an active part in both of them.19 Suppressing
platelet aggregability is an integral component in the man-
agement of coronary artery disease. The rationale for using
clopidogrel in patients with a history of cardiac surgery has
been validated in the Clopidogrel versus Aspirin in Patients
at Risk of Ischemic Events study.20 The RR reduction of
29% in the incidence of vascular death, stroke, MI, or
rehospitalization in the CABG subgroup exceeded the
beneﬁts seen in the general Clopidogrel versus Aspirin in
Patients at Risk of Ischemic Events study population.20 In
the Clopidogrel in Unstable angina to prevent Recurrent
Events trial, clopidogrel proved superior to placebo in the
prevention of MACCE.21 The degree of risk reduction with
dAPT paralleled the patient complexity, with the greatest
beneﬁt seen in the higher risk subgroups.21 The reduction in
the frequency of MACCE with dAPT was also represented
in the CABG subgroup (RR 0.89, 95% CI 0.71 to 1.11).22
The composite end point of death and recurrent MI was also
seen less frequently in a cohort of patients with MIrevascularized with CABG who were taking clopidogrel.11
Furthermore, graft patency was improved by the dAPT
protocol in comparison with aspirin monotherapy.3,23 Gao
et al3 randomized CABG patients to receive either aspirin
only (n ¼ 124) or aspirin plus clopidogrel (n ¼ 125).
Computed tomographic imaging revealed better saphenous
vein graft patency in the dual antiplatelet treatment arm. In a
similar study design, Sun et al23 suggested that, in the 79
patients who completed angiographic follow-up, clopidogrel
was superior to placebo in preventing radial artery graft
failure. A caveat worth noting was that only a low-mainte-
nance aspirin dose was administered (81 to 100 mg) in the
monotherapy arm in the latter trials,3,23 which has been
found to incompletely inhibit TxA2 production after
CABG.24 The impact of individual responsiveness to aspirin
was not reported in these studies.3,23 The combination of
clopidogrel and aspirin also resulted in superior clinical out-
comes in patients who underwent off-pump coronary artery
bypass surgery.25 The higher postoperative platelet respon-
siveness in off-pump coronary artery bypass in comparison
with conventional patients with CABG, as determined by
P-selectin expression, adds credibility to strategies intensi-
fying the platelet inhibition in this subpopulation.26 The
potential advantages of dual antiplatelet inhibition notwith-
standing its beneﬁts have not been generally demonstrable in
all trials investigating its impact. In the Clopidogrel for High
Atherothrombotic Risk and Ischemic Stabilization, Manage-
ment, and Avoidance trial evaluating patients with stable
cardiovascular disease, dAPT was ineffective in reducing the
composite end point of death, MI, or stroke.27
Our study differed from the aforementioned trials in that
it speciﬁcally targeted the CABG subpopulation that
retained high platelet aggregability despite aspirin therapy.
We found that 51% of patients who underwent elective
CABG had incomplete inhibition of platelet reactivity with
aspirin. The utilized aggregometry-based algorithm for
discriminating between aspirin responders and non-
responders had a distinct advantage in the comparison with
conventional coagulation tests. It used whole blood at the
patient’s own temperature for analysis, thereby measuring
platelet activity within their physiological milieu. Similar
incidences of post-CABG aspirin resistance were previously
reported.6 Our study revealed multiple facets of post-
operative hypercoagulability. We found that the surgical
procedure elicited an increase in both ﬁbrinogen levels and
platelet reactivity. Although there are data to suggest that
aspirin resistance postoperatively is a transient phenome-
non,28 this observed early hypercoagulability may render the
grafts particularly vulnerable during this period. The parallel
and synergistic inhibitions of the cyclooxygenase-1 and
ADP-mediated platelet activation pathways result in
ampliﬁcation of platelet inhibition,5 which we hypothesized
to be potentially useful in patients exhibiting single anti-
platelet drug resistance. Our trial, however, did not prove
that the combination of aspirin and clopidogrel was superior
in reducing the frequency of the primary end point to aspirin
monotherapy in aspirin-resistant patients with CABG. These
results mirror the observations from a retrospective analysis
of propensity-matched cohorts, which also found no sur-
vival beneﬁt for dAPT over aspirin after CABG.29
Furthermore, 1-year saphenous vein graft intimal
1666 The American Journal of Cardiology (www.ajconline.org)hyperplasia, as documented by intravascular ultrasound, in
the Clopidogrel After Surgery for Coronary Artery DiseasE
study was not improved by dAPT (n ¼ 46) in comparison
with an aspirin-only antiplatelet regime (n ¼ 44).4 Our data
did, however, suggest that patients <65 years and those with
a body mass index >30 kg/m2 might beneﬁt from dAPT in
the setting of aspirin resistance. This gain was not offset by
increasing bleeding events in neither the entire study cohort
nor any of the subgroups. We believe that a study evaluating
the potential of these aspirin-resistant subgroups to capi-
talize on enhancement of antiplatelet therapy is warranted.
Our study has signiﬁcant limitations. The estimation of
the sample size required to test the null hypothesis was based
on an exact binomial test power analysis.18 We cannot reli-
ably exclude the possibility that the study may have been
underpowered. In fact, a nonsigniﬁcant 39% RR reduction in
the primary end point was noted with the addition of clopi-
dogrel to aspirin in the context of aspirin resistance. Our
results may provide an impetus for the conduct of a larger
scale study of a similar design. Another potential drawback
of our study stems from the lack of an unequivocal deﬁnition
of aspirin resistance. Aggregometry in our study revealed a
continuum in individual platelet inhibition responses to
aspirin. The cut-off points of multiple platelet function tests
differentiating between aspirin response and resistance are
based on the deﬁnition, rather than unambiguous clinical
data supporting their relevance. Furthermore, different lab-
oratory pathway descriptors of platelet function yield vary-
ing incidences of high on-therapy residual platelet reactivity.
One should, therefore, resist extrapolating results based on
one platelet assessment instrument onto a larger group of
platelet function tests, until conﬁrmation of interchange-
ability has been established.Acknowledgment: We thank Milan Milosevic for
providing expert statistical advice.Disclosures
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